Novel monoclonal antibodies to the SERINC5 HIV-1 restriction factor for detection of endogenous and virion-associated SERINC5.
The cellular transmembrane protein serine incorporator 5 (SERINC5) has been identified as an HIV-1 restriction factor. The characterization of SERINC5 protein expression and sub-cellular localization has been limited to exogenously expressed SERINC5 as very few monoclonal antibodies (mAbs) of sufficient specificity and sensitivity are currently available. This technology is comprised of novel, highly specific and cost effective anti-SERINC5 mAbs. These mAbs are used in detection and quantification of SERINC5 in multiple cell lines that are used in HIV-1 research. The novel mAbs provide valuable tools to study several mechanisms of SERINC5 action, including HIV-1 restriction, neuronal plasticity and the role of SERINC5 in lipid rafts in cancer, and could potentially be engineered to serve as therapeutic tools.
- Identification and quantification of SERINC5 in multiple cell lines
- Detection of virion associated SERINC5
- Characterization of endogenous levels of SERINC5
- Utility in Flow Cytometry, Western Blot, and Immunocytochemistry.
- Highly specific to SERINC5
- Endogenous detection of SERINC5 in whole cells for localization of HIV-1
- Quantification of SERINC5 levels on the cell surface
- Multiple antibodies that recognize three SERINC5 domains
- Cost effective in comparison to other polyclonal anti-SERINC5 Abs.
- Available for Cooperative Research and Development collaborations
- Hybridomas and mAbs available for licensing as research tool for laboratory research
- mAbs sequences can be made available for commercial recombinant protein expression.